Sign in to view content

Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation

Tarek S. Hassan, MD, FASRS

Video
Published 2020

Related

Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials
Caroline Baumal, MD
Annual Meeting Talks
2022
Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database
Anita Barikian, MD
Annual Meeting Talks
2022
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more